Get the Stockscreener App
6.74
0.88%
-0.06
After Hours:
6.74
Neuraxis Inc stock is traded at $6.74, with a volume of 110.77K.
It is down -0.88% in the last 24 hours and down -7.29% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$6.80
Open:
$6.82
24h Volume:
110.77K
Relative Volume:
0.85
Market Cap:
$83.47M
Revenue:
$4.28M
Net Income/Loss:
$-7.28M
P/E Ratio:
-8.274
EPS:
-0.8146
Net Cash Flow:
$-6.17M
1W Performance:
-1.75%
1M Performance:
-7.29%
6M Performance:
+47.48%
1Y Performance:
+143.32%
1-Day Range:
$6.57
$6.87
1-Week Range:
$6.57
$7.27
52-Week Range:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
6.74 | 84.21M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Neuraxis Inc Stock (NRXS) Latest News
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Neuraxis, Inc. Revenue Breakdown – AMEX:NRXS - TradingView
Form S-3 Neuraxis Inc For: 24 July By Investing.com - Investing.com South Africa
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Beat Despite Negative Bottom Line, Stock SlidesEarnings Season Preview - DonanımHaber
Neuraxis, Inc. Files Form 8-K with SEC: Company Details, Address, and Stock Listing on NYSE American - Minichart
NeurAxis Declares Q2 Stock Dividend on Series B - TipRanks
Neuraxis declares stock dividend for Series B preferred, ~80,463 common shares to be issued - TradingView
NRXSNeuraxis Inc Latest SEC Filings - Finviz
Neuraxis Inc. (NRXS) Holds Steady Near Resistance Amid Low Volatility SessionVolatility Stop - dars.gov.et
Neuraxis Inc. (NRXS) Hovers Near Key Support Level After Modest DeclineMACD Signal Stocks - dars.gov.et
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Growth Benchmark - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to sales forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Price to book forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to revenue forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to earnings forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBITDA forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentProfit Inflection Point - dars.gov.et
NeurAxis, Inc. Actuals & Estimates (AMEX:NRXS) - TradingView
NRXS Forecast — Price Target — Prediction for 2027 - TradingView
Neuraxis Inc (NRXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRXS Q1 2026 Earnings: EPS Surprises to the Upside, Stock Climbs 6.56%Earnings Surprise Stocks - dars.gov.et
Neuraxis Inc. (NRXS) Surges 6.56% as Momentum Builds Above Key SupportMid Cap Momentum - dars.gov.et
Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Institutional Confidence - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc. (NRXS) Holds Steady Near Support Level as Market Awaits CatalystBreadth Thrust - dars.gov.et
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Forecast Report - dars.gov.et
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsRetail Earnings Report - dars.gov.et
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower Loss Beats Estimates as Development Milestones AdvanceEarnings Deceleration Risk - dars.gov.et
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Cap:
|
Volume (24h):